Literature DB >> 15865430

Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin.

Maria Nunes1, Joshua Kaplan, Joseph Wooters, Malathi Hari, Albert A Minnick, Michael K May, Celine Shi, Sylvia Musto, Carl Beyer, Girija Krishnamurthy, Yongchang Qiu, Frank Loganzo, Semiramis Ayral-Kaloustian, Arie Zask, Lee M Greenberger.   

Abstract

A synthetic analogue of the tripeptide hemiasterlin, designated HTI-286, depolymerizes microtubules, is a poor substrate for P-glycoprotein, and inhibits the growth of paclitaxel-resistant tumors in xenograft models. Two radiolabeled photoaffinity analogues of HTI-286, designated 4-benzoyl-N,beta,beta-trimethyl-l-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]-N(1),3-dimethyl-l-valinamide (probe 1) and N,beta,beta-trimethyl-l-phenylalanyl-4-benzoyl-N-[(1S,2E)-3-carboxy-1-isopropyl-2-butenyl]-N,beta,beta-trimethyl-l-phenylalaninamide (probe 2), were made to help identify HTI-286 binding sites in tubulin. HTI-286, probe 1, and probe 2 had similar affinities for purified tubulin [apparent K(D(app)) = 0.2-1.1 microM], inhibited polymerization of purified tubulin approximately 80%, and were potent inhibitors of cell growth (IC(50) = 1.0-22 nM). Both radiolabeled probes labeled exclusively alpha-tubulin. Labeling by [(3)H]probe 1 was inhibited by probe 1, HTI-286, vinblastine, or dolastatin 10 (another peptide antimitotic agent that depolymerizes microtubules) but was either unaffected or enhanced (at certain temperatures) by colchicine or paclitaxel. [(3)H]Probe 1 also labeled exclusively tubulin in cytosolic extracts of whole cells. The major, if not exclusive, contact site for probe 1 was mapped to residues 314-339 of alpha-tubulin and corresponds to the sheet 8 and helix 10 region. This region is known to (1) have longitudinal interactions with beta-tubulin across the interdimer interface, (2) have lateral interactions with adjacent protofilaments, and (3) contact the N-terminal region of stathmin, a protein that induces depolymerization of tubulin. Binding of probe 1 to this region may alter the conformation of tubulin outside the labeling domain, since enzymatic removal of the C-terminus of only alpha-tubulin by subtilisin after, but not before, photolabeling is blocked by probe 1. These results suggest that hemiasterlin is in close contact with alpha-tubulin and may span the interdimer interface so that it contacts the vinblastine- and dolastatin 10-binding sites believed to be in beta-tubulin. In addition, we speculate that antimitotic peptides mimic the interaction of stathmin with tubulin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15865430     DOI: 10.1021/bi0474766

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  4 in total

Review 1.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

2.  Tau stabilizes microtubules by binding at the interface between tubulin heterodimers.

Authors:  Harindranath Kadavath; Romina V Hofele; Jacek Biernat; Satish Kumar; Katharina Tepper; Henning Urlaub; Eckhard Mandelkow; Markus Zweckstetter
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-01       Impact factor: 11.205

3.  Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor.

Authors:  Lih-Ching Hsu; David E Durrant; Ching-Chun Huang; Nai-Wen Chi; Riccardo Baruchello; Riccardo Rondanin; Cinzia Rullo; Paolo Marchetti; Giuseppina Grisolia; Daniele Simoni; Ray M Lee
Journal:  Invest New Drugs       Date:  2011-06-08       Impact factor: 3.850

4.  Total synthesis and cytotoxicity of the marine natural product malevamide D and a photoreactive analog.

Authors:  Werner Telle; Gerhard Kelter; Heinz-Herbert Fiebig; Peter G Jones; Thomas Lindel
Journal:  Beilstein J Org Chem       Date:  2014-02-03       Impact factor: 2.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.